Brivaracetam
An anticonvulsant medication used as adjunctive therapy in adults and children with focal-onset seizures. It binds to a specific protein in nerve terminals called SV2A to modulate neurotransmitter release and reduce excessive neuronal firing. It has a rapid onset of action and is available in both oral and intravenous formulations.
Molekularmasse
212,2900 g/mol
LogP
1,00
TPSA
63,40 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1
InChI
InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
Molecular Formula
C11H20N2O2
HBD / HBA
1 / 2
Rotierbare Bindungen
5
Schwere Atome
15
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An anticonvulsant medication used as adjunctive therapy in adults and children with focal-onset seizures. It binds to a specific protein in nerve terminals called SV2A to modulate neurotransmitter release and reduce excessive neuronal firing. It has a rapid onset of action and is available in both oral and intravenous formulations.
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.
Yes, Brivaracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL607400. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9837243. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brivaracetam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brivaracetam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brivaracetam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brivaracetam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brivaracetam"></drugfyi-drug>